Heart failure & cardiomyopathiesMeta-analysis
Dapagliflozin and Quality of Life Measured Using the EuroQol 5-Dimension Questionnaire in Patients with Heart Failure with Reduced and Mildly Reduced/Preserved Ejection Fraction
- Pooled patient-level analysis of the DAPA-HF and DELIVER randomised trials
Authors' conclusion
Both higher (better) EQ-5D-5L VAS and index scores were associated with better outcomes. Dapagliflozin treatment improved EQ-5D-5L VAS and index scores, irrespective of ejection fraction.
Study context
- Population
- Patients with HF and reduced ejection fraction (HFrEF) (DAPA-HF) and HFmrEF/HFpEF (DELIVER)
- Comparison
- EQ-5D-5L visual analogue scale (VAS) score quartiles; dapagliflozin effect on EQ-5D-5L scores
- Outcome
- Composite of:
- CV death
- Worsening heart failure (HF)
Pooled result
As reported in the abstract
CV death or worsening HF by EQ-5D-5L VAS quartile
Each group vs Q1Hazard ratio (95% CI)
Q2
0.81(0.72–0.91)
Q3
0.74(0.65–0.84)
Q4
0.62(0.54–0.72)
Further pooled results
Components of the composite and all-cause death
- Lower risk in patients with better scores
EQ-5D-5L index score and outcomes
- Similar findings as for VAS score
Effect of dapagliflozin on EQ-5D-5L VAS and index scores
- Dapagliflozin improved both scores across the range of EF
Original publication
Dapagliflozin and Quality of Life Measured Using the EuroQol 5-Dimension Questionnaire in Patients with Heart Failure with Reduced and Mildly Reduced/Preserved Ejection Fraction. Eur J Heart Fail. Published 3 May 2024. doi:10.1002/ejhf.3263
Summarised from the published abstract; every number is checked against it